135 related articles for article (PubMed ID: 31515574)
1. Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin's lymphoma patients.
Nachmias B; Sandler V; Slyusarevsky E; Pogrebijski G; Kritchevsky S; Ben-Yehuda D; Goldschmidt N; Gatt ME
Ann Hematol; 2019 Nov; 98(11):2561-2567. PubMed ID: 31515574
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Central Nervous System (CNS) Involvement in Children With Non-Hodgkin's Lymphoma (NHL) and the Diagnostic Value of CSF Flow Cytometry in CNS Positive Disease.
Huang S; Jin L; Yang J; Duan Y; Zhang M; Zhou C; Zhang YH
Technol Cancer Res Treat; 2021; 20():15330338211016372. PubMed ID: 34060372
[TBL] [Abstract][Full Text] [Related]
4. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.
Bierman P; Giglio P
Hematol Oncol Clin North Am; 2005 Aug; 19(4):597-609, v. PubMed ID: 16083825
[TBL] [Abstract][Full Text] [Related]
6. The incidence of secondary central nervous system involvement in patients with non-Hodgkin's lymphoma as detected by 18F-FDG PET/CT.
Akkas BE; Vural GU
Nucl Med Commun; 2013 Jan; 34(1):50-6. PubMed ID: 23111376
[TBL] [Abstract][Full Text] [Related]
7. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
Sandlund JT; Murphy SB; Santana VM; Behm F; Jones D; Berard CW; Furman WL; Ribeiro R; Crist WM; Greenwald C; Chen G; Walter A; Pui CH
J Clin Oncol; 2000 Aug; 18(16):3018-24. PubMed ID: 10944136
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system lymphoma newly developed 12 years after remission of an ocular adnexal lymphoma.
Morikawa K; Tsuji T; Yamasaki H; Toyozumi Y; Arima N; Ohshima K; Tsuda H
Acta Haematol; 2013; 130(4):247-50. PubMed ID: 23860499
[TBL] [Abstract][Full Text] [Related]
9. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.
Zinzani PL; Magagnoli M; Frezza G; Prologo G; Gherlinzoni F; Bendandi M; Albertini P; Babini L; D'Alessandro R; Tura S
Leuk Lymphoma; 1999 Feb; 32(5-6):571-6. PubMed ID: 10048430
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
[TBL] [Abstract][Full Text] [Related]
11. Characteristic features of malignant lymphoma with central nervous system involvement.
Yoshida S; Morii K; Watanabe M; Saito T
Surg Neurol; 2000 Feb; 53(2):163-7. PubMed ID: 10713195
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas.
Cingolani A; Gastaldi R; Fassone L; Pierconti F; Giancola ML; Martini M; De Luca A; Ammassari A; Mazzone C; Pescarmona E; Gaidano G; Larocca LM; Antinori A
J Clin Oncol; 2000 Oct; 18(19):3325-30. PubMed ID: 11013271
[TBL] [Abstract][Full Text] [Related]
13. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes.
Gleissner B; Siehl J; Korfel A; Reinhardt R; Thiel E
Neurology; 2002 Feb; 58(3):390-6. PubMed ID: 11839837
[TBL] [Abstract][Full Text] [Related]
14. CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course.
Ekstein D; Ben-Yehuda D; Slyusarevsky E; Lossos A; Linetsky E; Siegal T
J Neurol Sci; 2006 Aug; 247(1):39-46. PubMed ID: 16678210
[TBL] [Abstract][Full Text] [Related]
15. Isolated CNS Hodgkin's lymphoma: implications for tissue diagnosis.
Martinez DL; Gujrati M; Geoffroy F; Tsung AJ
CNS Oncol; 2014 Nov; 3(6):383-7. PubMed ID: 25438809
[TBL] [Abstract][Full Text] [Related]
16. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough?
O'Neill BP; Dinapoli RP; Kurtin PJ; Habermann TM
J Neurooncol; 1995; 25(1):67-71. PubMed ID: 8523091
[TBL] [Abstract][Full Text] [Related]
17. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma. The Massachusetts General Hospital experience 1958-1989.
Miller DC; Hochberg FH; Harris NL; Gruber ML; Louis DN; Cohen H
Cancer; 1994 Aug; 74(4):1383-97. PubMed ID: 8055462
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.
Hollender A; Kvaloy S; Lote K; Nome O; Holte H
Eur J Cancer; 2000 Sep; 36(14):1762-8. PubMed ID: 10974623
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system involvement in patients with mantle cell lymphoma.
Oinonen R; Franssila K; Elonen E
Ann Hematol; 1999 Mar; 78(3):145-9. PubMed ID: 10211757
[TBL] [Abstract][Full Text] [Related]
20. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma.
Bashir RM; Bierman PJ; Vose JM; Weisenburger DD; Armitage JO
Am J Clin Oncol; 1991 Dec; 14(6):478-82. PubMed ID: 1720278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
